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Introduction
Long-term survival following orthotopic lung transplantation is 
affected by the development ofchronic lung allograft dysfunction 
which would include bronchiolitis obliterans syndrome and 
restrictive allograft dysfunction. This affects 50-60% of  patients 
5 years out from surgery and 90-100% by year 9 [1]. The 
pathogenesis of  CLAD is poorly understood, but several possible 
mechanisms for the development of  this disease process suggest 
that different inflammatory insults such as ischemia-reperfusion, 
infection and/or rejection can lead to the development of  CLAD 
[2]. Acute cellular rejection is the most consistently described risk 
factor for allograft lung dysfunction [3]. Both acute rejection and 
lymphocyte bronchiolitis are associated with the increased risk of  
this syndrome . Attenuating autoimmune T-cell mediated damage 
to the lung allograft should reduce bronchial epithelial injury 
and fibro proliferative events [4]. Novel therapies aimed at even 
more aggressive T-cell depletion with the use of  alimentation and 
anti-CD52 antibody has generated interest both as an induction 
agent and therapeutic agent to stabilize and improve pulmonary 
function [5]. 
Autoimmunity could also produce CLAD . Tissue injury exposes 
normally sequestered self-antigens and their fragments which 
act as triggers for auto reactive T-cell proliferation and antibody 
production. Type 5 collagen (Coll V) resides beneath the 
basement membrane of  the perivascular and peribronchiolarlung 
tissue. Upon exposure to Coll (V) fragments, auto reactive T-cells, 
specific to Type 5 collagen, proliferate and secrete cytokines 
consistent with a Th1 response [6]. In patients with elevated 
Type 5 collagen cell mediated immunity, a 5-10 fold increased 
risk of  high grade bronchiolitis obliterans  was noted [7]. The 
use of  cardiopulmonary bypass during lung transplant has also 
been associated with the development of  BO [8]. Previous 
studies have predominantly found that the use of  CPB for 
lung transplant may produce an inflammatory response that is 
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Background:  The use of  Cardiopulmonary Bypass (CPB) in lung transplantation remains controversial. The goal of  this 
study was to determine whether lung transplant with CPB affects lung function or development of  bronchiolitis obliterans 
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p=.07. 56% of  bypass patients, vs 39% of  non-bypass, showed no evidence of  rejection. CPB patients also had less single 
rejection episodes 20% vs 30%. FEV1 improved from baseline over the first year in both groups and improved over the 
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Conclusion:  Cardiopulmonary bypass appeared to have no deleterious effect on FEV1 or rejection. CPB may provide a 
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often indistinguishable from ischemia/reperfusion injury [8]. 
The integrity of  the endothelium plays an integral role in this 
mechanism of  lung injury by regulating the intervention between 
pulmonary vasodilation and vasoconstriction. This vasomotor 
dysfunction in the transplanted lung is associated with an acute 
rise in pulmonary vascular resistance [9]. During CPB the 
transplanted lung is reperfused with activated blood elements 
that may exacerbate this reperfusion injury [10]. Although it 
seems intuitive that CPB, known to produce an inflammatory 
response and requires full systemic anticoagulation, would have 
a negative impact on function, there is still controversy over the 
extent to which CPB contributes to morbidity and death. Some 
have reported no adverse effects of  CPB on length of  intubation 
or duration of  ICU stay [11]. In fact, some believe that the use 
of  CPB reduces ischemic reperfusion injury during allograft 
implantation along with its immunosuppressive effects, both on 
a humoral level by depleting compliment factors and on a cellular 
level with a decrease in cell numbers of  the innate and adaptive 
system, potentially improving survival. There have been few 
studies to date investigating the relationship between the use of  
CPB and the associated development of  BO.
This study seeks to determine if  there is an association between 
CPB and the development of  CLAD in orthotopic lung transplant 
patients. 
Materials and Methods
After obtaining approval from the Institutional Review Board of  
Loyola University Chicago’s Health Sciences Division (Protocol 
#109643) on 8/27/07 to access patient records, 151 patients 
who underwent unilateral or bilateral orthotropic lung transplant 
from 2002-2012 were evaluated. The committee waived patient 
consent since the retrospective analysis did not submit any 
patient identifiers when reporting the findings of  this study. The 
patients were chosen over this time frame because the surgical 
teams were similar and non-heparinized circuits were used until 
2012 when Trillium Biosurface (Medtronic Inc. Minneapolis, 
MN55432) polymer coating with heparin was used on circuits 
and oxygenators. Patients were identified using the Department 
of  Pulmonology and UNOS database. The patients were divided 
into two groups according to the use of  cardiopulmonary bypass 
or if  patients had sequential placement of  the lungs without 
the use of  bypass. Demographic information was collected 
from the patients, and the disease process which required lung 
transplantation was also recorded. Other information collected 
was cardiopulmonary bypass times, total surgery and anesthesia 
times, number of  post-op days ventilated, and total time in the 
ICU. Patients were followed for three years and the number of  
patients who had a biopsy proven acute rejection was recorded. 
Transbronchial biopsies were performed at 1, 3, 6, 9 and 12 
months post-transplant and upon clinical indication. This was 
continued at 15, 18 and 24 months if  significant cellular rejection 
was found during the first year. Also, if  patients had more than 
one episode of  rejection as documented by symptoms after a 3 
month symptom free period, the total number of  rejections was 
recorded. Bronchiolitis obliterans syndrome is defined by the 
ISHLT as a greater than 20% decline in forced expiratory volume 
in 1 second or in forced expiratory flow, mid expiratory phase, in 
the absence of  acute rejection or infection [12]. FEV-1 values were 
used as a surrogate to follow the development of  bronchiolitis 
obliterans. Average percent change in FEV-1 was recorded in each 
year and overall change in FEV-1 was recorded in each patient 
over the three year study period. The patients were divided into 
two groups according to the use or absence of  cardiopulmonary 
bypass. Demographic data were compared between the bypass or 
non-bypass group. Total surgery and anesthesia times were also 
compared between groups, as was total postoperative intubation 
and ICU times. Percentage of  patients who had no biopsy 
evidence of  rejection was compared between groups, as was the 
number who had one or more episodes of  rejection. These were 
also compared between bypass and non-bypass groups. FEV-1 
volume and percent change from immediate post bypass values 
were compared between groups. Patients who survived less than 
six months due to complications or rejection were excluded from 
the data set. 
No power analysis was performed since this study evaluated all 
patients who underwent a single or double lung transplant over 
a 10 year period. Differences between bypass and non-bypass 
groups in numeric value were performed by t-test with Levene’s 
test used for equality. Non-numeric values were compared using 
Fisher’s Exact t-test.All values are expressed as mean ± SD and p 
< 0.05 was used as the level to denote significance.
Results
One hundred and fifty one charts were reviewed with one 
hundred and forty seven patients being evaluated. Demographics 
and disease type for all patients are demonstrated in Table 1. The 
number of  postoperative days ventilated was higher in patients 
who under went cardiopulmonary bypass (Table 2). Total time in 
the CV ICU tended to be longer in CPB patients but significant 
difference between the groups was not noted. The number of  
episodes of  biopsy proven acute rejection was lower in the group 
that under went cardiopulmonary bypass compared to those that 
had sequential placement of  the lungs without bypass (Table 3). A 
majority of  patients with lung rejection were noted to have Grade 
A2 lung rejection patterns with 5% of  patients demonstrating 
Grade B1R airway inflammation. 60% of  the patients who 
underwent cardiopulmonary bypass had no evidence of  acute 
rejection over a 3 year period compared to 30% of  patients who 
did not receive CPB (Table 3). There also seemed to be more 
episodes of  rejection over time in the group that did not undergo 
cardiopulmonary bypass (Table 3). FEV-1 was more improved 
from baseline at year one in the bypass group (Table 4). This 
stabilization in pulmonary function compared to baseline values 
was even more marked at year two after transplant in the bypass 
group compared to the non-bypass patients. By year three, FEV-1 
plateaued in the bypass group and demonstrated a slight decrease 
in the non-bypass patients. 
Discussion
This retrospective review of  patients who have undergone 
orthotopic unilateral or bilateral lung transplant either with 
cardiopulmonary bypass or by sequential implantation without 
bypass demonstrates that in the early postoperative period 
patients who underwent their transplant using CPB actually 
experienced an improvement in lung function over baseline 
at year 1 and 2 which plateaued at year 3. They also had less 
episodes of  acute rejection compared to non-bypass patients, 
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Use of  CPB Absence of  CPB
n 30 121
Average Age 47.0 ± 15.1 51.6 ± 12.5
Total Males (%) 20 56
Total Females (%) 10 65
Cystic Fibrosis 5 13
Pulmonary Fibrosis + IPF 17 40
COPD 0 23
Emphysema 1 26
A1A 1 6
Sarcoidosis 2 4
Scleroderma 1 1
LAM 1 3
Langerhans Histiocytosis 0 1
Primary Graft Dysfunction 0 0
BOS 0 2
Bronchiectasis 1 1
Other 1 1
Single LTx 2 77
Double 8 44
Table 1. Demographic Data for Patients Undergoing Lung Transplant
Table 2. Postoperative Days Ventilated and ICU Stay
   Use of  CPB Absence of  CPB
Post-op Days Ventilated 4.8 ± 7.4 2.3 ± 4.3    p = 0.002
Days in ICU 7.9 ± 4.4 4.1   ± 2.9   p = 0.16
Table 3. Incidence of  Episodes of  Acute Rejection - Percent of  Subjects
Use of  CPB 0 1 2 3 4 5
Yes 60* 20 17 0 3 0
No 38 29 15 11 5 2
Table 4. FEV1 % change from Baseline Values Year After Treatment
1 2 3
Use of  CPB 12.5 ± 3.2 19.1 ± 4.3* 19.4 ± 5.9*
No CPB 7.3 ± 0.9 11.2 ± 1.5 9.9 ± 2.3
*p < 0.05 compared to No CPB
*p = 0.023
which suggests a possible immunosuppressive effect of  
cardiopulmonary bypass. These findings may also be attributable 
to a possible reduction in ischemic stress offered by continuous 
perfusion with cardiopulmonary bypass not observed with off-
pump transplant patients. Other investigators have demonstrated 
that cardiopulmonary bypass was associated with allograft 
dysfunction [13]. These investigators found that the patients who 
underwent CPB had poorer lung function with more pronounced 
infiltrate than the no CPB group. In addition, their intubation 
time was markedly longer,10 days, and the length of  ICU stay 
was also prolonged. In our study, the bypass group was intubated 
longer than the off-pump group (5 days vs 2 days) respectively. 
But our intubation times were markedly reduced and more in 
line with other studies where CPB patients were intubated 5-6 
days compared to 2 days in non-bypass transplant patients [14-
15]. This was probably related to diminished cardiopulmonary 
bypass times which averaged around 200 minutes in our study and 
diminished inflammatory response secondary to the disease state 
of  the patient requiring lung transplantation. A large amount of  
the patients in the Gammie study had pulmonary hypertension, 
whereas other studies, including the present, had pulmonary 
fibrosis, cystic fibrosis or COPD as their primary diagnosis for 
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transplant.
Several studies have demonstrated a positive effect of  
cardiopulmonary bypass on lung  function after lung transplantation 
[11]. With sequential lung transplantation,  the first implanted 
allograft is subjected to increased ischemia-reperfusion injury 
during the implantation of  the second allograft. This could occur 
from the entire cardiac output being diverted to the first implanted 
allograft, resulting in increased blood flow and pressure. The 
use of  CPB ensures stable hemodynamics during implantation 
and facilitates difficult recipient dissection. One study found no 
significant difference in postoperative mechanical ventilation 
requirements between CPB and non-bypass groups [11]. Our 
study found a definite prolongation in mechanical ventilation in the 
CPB group, but the difference was only 2 days compared to other 
studies which showed similar differences in length of  ventilation 
[14-15]. Survival after CPB was not different when compared to 
non-bypass patients after lung transplant.  Triantafillou et al., [16] 
found no difference between CPB and non-bypass groups in time 
spent in the ICU, time to reach a PO2 of  > 60 mmHg on RA 
and survival. Survival was also similar between bypass the non-
bypass lung transplant patients in another study by Hlozek [15]. 
In our study, it seemed that CPB improved overall outcomes by 
reducing the overall number of  episodes of  rejection compared 
to non-bypass patients and improving overall lung function with 
better FEV1 percent improvement over baseline at 1 and 2 years 
which was maintained in the third year. This finding seems to 
support the observation that CPB may be more beneficial than 
detrimental to overall outcomes after lung transplantation.
Study limitations are related to the fact that this is a retrospective 
analysis with a lack of  control concerning anesthetic technique. 
Also, the use of  transesophageal echocardiography and type 
of  thoracotomy, which could affect the development of  
oropharyngeal dysphagia, were not controlled. Nevertheless, 
this study demonstrates that patients who underwent lung 
transplant with the use of  cardiopulmonary bypass had minimal 
development of  CLAD compared to those who had off-pump 
transplant. In addition, the clinical degree of  rejection noted in all 
patients was mild and did not appreciably affect the FEV1 values 
noted during routine progress visits in these patients. 
Conclusions
Our findings support the observation that cardiopulmonary 
bypass is a safe and effective method for lung transplantation and 
does not increase the risk of  bronchiolitis obliterans or rejection 
in this patient population. Patients who underwent lung transplant 
with cardiopulmonary bypass actively experienced a transient 
increase in lung function during the second postoperative year 
with the episodes of  rejection diminished. This suggests a possible 
immune suppressive effect with bypass or diminished ischemic 
stress to the lungs afforded by bypass as compared to off-pump 
sequential transplant. 
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